UBS raised the firm’s price target on Aveanna (AVAH) to $5 from $4.50 and keeps a Sell rating on the shares. Aveanna Healthcare’s Q1 results were broadly positive, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVAH: